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Metallothionein regulates intracellular zinc
signaling during CD4+ T cell activation
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Abstract
Background: The ultra-low redox potential and zinc binding properties of the intracellular pool of mammalian
metallothioneins (MT) suggest a role for MT in the transduction of redox signals into intracellular zinc signals.
Increased expression of MT after exposure to heavy metals, oxidative stress, or inflammatory cytokines leads to an
increased intracellular redox-mobilizable zinc pool that can affect downstream zinc-sensitive signaling pathways.
CD4+ T helper cells are poised to be influenced by MT transduced zinc signaling because they produce intracellular
reactive oxygen species following activation through the T cell receptor and are sensitive to small changes in
intracellular [Zn2+].
Results: MT expression and intracellular [Zn2+] are both increased during primary activation and expansion of naïve
CD4+ T cells into the Tr1 phenotype in vitro. When Tr1 cells from wildtype mice are compared with congenic mice
lacking functional Mt1 and Mt2 genes, the expression of intracellular MT is associated with a greater increase in
intracellular [Zn2+] immediately following exposure to reactive oxygen species or upon restimulation through the T
cell receptor. The release of Zn2+ from MT is associated with a greater increase in p38 MAPK activation following
restimulation and decreased p38 MAPK activation in MT knockout Tr1 cells can be rescued by increasing intracellular
[Zn2+]. Additionally, IL-10 secretion is increased in MT knockout Tr1 cells compared with wildtype controls and this
increase is prevented when the intracellular [Zn2+] is increased experimentally.
Conclusions: Differences in zinc signaling associated with MT expression appear to be a result of preferential oxidation
of MT and concomitant release of Zn2+. Although zinc is released from many proteins following oxidation, release is
greater when the cell contains an intracellular pool of MT. By expressing MT in response to certain environmental
conditions, CD4+ T cells are able to more efficiently release intracellular zinc and regulate signaling pathways following
stimulation. The link between MT expression and increased zinc signaling following activation represents an important
immunomodulatory mechanism of MT and illuminates the complex role MT plays in shaping immune responses.
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Background
Metallothioneins (MT) are low molecular weight, high
cysteine content proteins that are expressed in most
mammalian cells. Their upregulation in response to in-
creases in intracellular zinc ion concentration ([Zn2+]i),
reactive oxygen species (ROS), pro-inflammatory cyto-
kines, and as part of proliferation and differentiation [1]
suggests that MT may play an important role during the
development of immune responses. Specifically, we
hypothesize that upregulated MT expression can affect
both intracellular redox and zinc signaling events that
occur during CD4+ T helper cell activation. The release
of zinc ions by MT in response to redox signaling may
play a role in immune responses by directly influencing
zinc signaling pathways during CD4+ T helper cell
activation.
The intracellular labile zinc concentration has recently
been recognized as an important component of T cell
activation [2]. Modest increases in [Zn2+]i (in the range
of 200pM–1nM) can have profound effects on signaling
pathways originating from the T cell receptor (TcR) [3],
cytokine receptors [4, 5] and toll-like receptors [6].
Increases in [Zn2+]i inhibit the activity of selected
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intracellular kinases [7–9] and phosphatases [10, 11]
which, in turn, affect STAT and MAPK signaling net-
works and their associated transcription factor activity.
Regulating [Zn2+]i, therefore, has the potential to
dramatically influence the development of CD4+ T cell
effector function [12–14] and diseases that arise from
abnormal CD4+ T cell activity.
MT binds and releases zinc under physiologically
relevant conditions and, in concert with the families of
cell-specific zinc importers (Zip) and exporters (ZnT), is
part of a network that tightly controls intracellular [Zn2+]I
[15]. The intracellular pool of MT is a mixture of oxidized,
reduced and zinc bound forms of the protein [16, 17],
and the dynamic equilibrium of these forms regulates
zinc availability in response to intracellular ROS. Inter-
estingly, zinc release from MT is possible even in the
reducing environment of the cytosol through reactions
with selenium redox catalysts [18, 19]. MT contains 20
cysteine residues which impart a very low redox poten-
tial (−366 mV), making it a preferential target for oxi-
dation when compared with other free thiols including
glutathione (GSH) [20, 21]. Of the seven zinc binding
sites in MT, three have a comparatively weak metal
binding affinity (logK = 10–7.7) [22] which facilitates
zinc release upon thiol oxidation and results in a down-
stream effect on enzyme activity [23]. This property
uniquely positions MT to transduce ROS signals into
zinc signals within the narrow ranges of redox and [Zn2+]i
fluctuations that occur during CD4+ T cell activation.
Naïve CD4+ T cells express low levels of MT [24, 25].
Upon activation, [Zn2+]i increases over time as a result
of the release of zinc stored in vesicles into the cyto-
plasm [12] and from increased zinc import from the
extracellular environment [3, 26]. This sustained zinc
signal [27] induces the expression of MT which supports
T cell proliferation [26]. During primary CD4+ T cell
activation and differentiation, extracellular cytokines,
including TNF-alpha, IL-1, IL-6, and IL-27 [28–30] and
glucocorticoids [31], also influence the expression of MT
and simultaneously drive T cell differentiation. Cells with
an increased concentration of cytoplasmic MT are then
positioned to more efficiently convert ROS signals into
zinc signals [32] during subsequent activation events,
which has the potential to affect CD4+ T helper cell
function.
In this report, we confirm that MT expression following
the primary activation of naïve CD4+ T cells is influenced
by the cytokine IL-27 [30]. Furthermore, we show that
expression of MT provides CD4+ T cells with a redox-
sensitive pool of intracellular zinc that can be mobilized
under conditions of oxidative stress or in response to
intracellular ROS generation following signaling through
the TcR. In the absence of functional Mt1 and Mt2 genes
(MT -/-), the increase in [Zn2+]i following redox signaling
is reduced, and this results in decreased p38 activation in
MT -/- cells which can be rescued by pharmacologically
increasing [Zn2+]i. These results demonstrate that MT
plays a role in CD4+ T cell activation by transducing ROS
signals into an increased [Zn2+]i that subsequently affects
downstream effector function.
Results
Activation and proliferation of CD4+ T cells is associated
with an increase in the concentration of intracellular
labile zinc ions ([Zn2+]i) [33] and the expression of
metallothioneins (MT) [25]. Manipulating [Zn2+]i [13, 34]
or MT expression [30, 35] during activation affects cell
signaling networks and cytokine secretion patterns. In
elderly populations, a decreased ability to regulate in-
creases in [Zn2+]i following CD4
+ T cell activation results
in increased MT expression and altered T cell function
[26, 36]. This suggests that zinc and MT are coordinately
regulated during activation and this allows CD4+ T cells to
respond appropriately in different environments.
To determine the degree to which CD4+ T cells regu-
late [Zn2+]i and MT expression during activation and
effector cell development, naïve CD4+ T cells were stim-
ulated using anti-CD3 and anti-CD28 antibodies in the
presence or absence of IL-27 to promote the develop-
ment of Tr1 or Th0 phenotypes, respectively [37, 38]. In
both culture conditions, expression of CD25 served as
an activation marker and was increased by 24 h post-
stimulation (Fig. 1a). After 6 days of culture, CD25 was
expressed by >95 % of CD4+ T cells in both conditions,
(Fig. 1b) indicating cell activation was not reduced in the
absence of IL-27 signaling.
An increase in [Zn2+]i in CD4
+ T cells activated under
Th0 inducing conditions was observed after 6 days
(Fig. 1c). This increase followed the expression of CD25,
indicating naïve CD4+ T cells maintain zinc homeostasis
in the time period following initial activation events. In
the presence of IL-27, [Zn2+]i was increased by 4 days
post activation (Fig. 1c) and after 6 days was significantly
higher than in cells induced under Th0 conditions
(Fig. 1d), suggesting a link between IL-27 signaling and
the regulation of [Zn2+]i during primary activation. Next,
we measured intracellular MT expression during the
same activation window. A modest increase in MT ex-
pression was observed 6 days after activation under Th0
inducing conditions while MT expression was increased
significantly when cells were activated in the presence of
IL-27 (Fig. 1e). This increased MT expression persisted
for at least two days after cells were transferred and
cultured in media alone (Fig. 1f ), identifying a 48 h tem-
poral window where altered MT expression could poten-
tially play a role during CD4+ T cells re-activation.
Interestingly, the increase in intracellular MT in naïve
CD4+ T cells 3 days after activation preceded a measurable
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increase in [Zn2+]i, indicating MT induction did not
require an increase in [Zn2+]i under these culture condi-
tions. However, the highest level of MT expression and
[Zn2+]i both occurred on day 6 (Fig. 1c, e), supporting the
well-established link between increased [Zn2+]i and MT
induction.
To determine if MT gene dose affects intracellular zinc
homeostasis during the development of Tr1 cells, the
[Zn2+]i in Mt1Mt2 knockout cells (MT
-/-) was compared
with wildtype congenic cells (MT+/+) during naïve CD4+
T cell activation. The same pattern of [Zn2+]i increase
following activation was observed in both MT+/+ and
MT-/- CD4+ T cells at each of the stages of Tr1 cell dif-
ferentiation (Fig. 1g), indicating that MT did not signifi-
cantly affect intracellular labile zinc homeostasis under





Fig. 1 [Zn2+]i and MT expression are regulated during CD4
+ T helper cell differentiation and affected by IL-27. Mononuclear cells were isolated
from spleens of C57BL/6 mice (n = 7) and stimulated for 6 days with anti-CD3 and anti-CD28 antibodies in the presence of IL-27 or without cytokines
to induce a Tr1 or Th0 phenotype of CD4+ T cells, respectively. a, b CD25 expression, (c, d) intracellular [Zn2+] and (e, f) MT expression in the CD4+ T
cell population were measured at 24-h intervals for 6 days. Histograms are representative of one Tr1 sample (solid line) and one Th0 sample (dotted line).
g Mononuclear splenocytes from metallothionein knockout mice (MT-/-) (n= 11) or congenic wildtype controls (MT+/+) (n= 11) were cultured under Tr1
inducing conditions for 6 days and then rested for an additional 2 days. Intracellular [Zn2+] was measured on Day 0, Day 6, and Day 8 which corresponded
to naïve, lymphoblast and effector stages of CD4+ T cell development, respectively. Error bars indicate standard deviation. *p< .05
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proliferating lymphoblasts were resuspended in fresh
media with no additional stimulation for 2 days, demon-
strating that the increase in the [Zn2+]i above 500 pM is
transient and associated with activation and the lympho-
blast phenotype.
The increased intracellular pool of zinc-MT that is
present after the development of the CD4+ Tr1 cell ef-
fector phenotype is a potential reservoir of zinc that can
be mobilized during reactivation. We assessed whether
this MT-bound zinc pool could be released in response
to reactive oxygen species (ROS) and affect [Zn2+]i.
Exposing CD4+ Tr1 cells to hydrogen peroxide (H2O2),
a biologically relevant oxidant associated with T cell acti-
vation [39], for 7 min resulted in an increase in [Zn2+]i
in a dose dependent manner (Fig. 2a). This size and
timing of this increase was unaffected by the addition
of 20 μM ZnSO4 to the media during the time tested
(Additional file 1: Figure S1), confirming that the increase
in [Zn2+]i was not due to an influx of extracellular zinc.
Oxidant-induced release of zinc was significantly greater
in MT+/+ CD4+ T cells than in MT-/- CD4+ T cells during
the initial 7 min of exposure when compared by linear
regression analysis (p < .05) (Fig. 2b and c).
To confirm that the oxidant-releasable zinc was se-
questered via a thiolate bond, the thiol-specific oxidant
DTDP was added to cells and the release of zinc was
measured over time. As with H2O2, the release of Zn
2+
following DTDP exposure was greater in MT+/+ Tr1
cells than in MT-/- Tr1 cells (p < .05) (Fig. 2d). The ro-
bust release of Zn2+ following either oxidant exposure,
irrespective of MT gene dose, confirms that MT is not
the only redox-sensitive mobilizable pool of intracellular
zinc (Fig. 2d). When a pool of zinc-MT is present,
however, exposure to ROS results in a faster and larger
increase in intracellular [Zn2+]I, indicating that MT con-
tributes to a more efficient transduction of an oxidant
signal into a zinc signal compared with other zinc-
bound proteins. This additional labile zinc has the
potential to inhibit the activity of several important T
cell protein tyrosine phosphatases [4, 10] and affect
downstream cell signaling.
Global changes in intracellular redox buffering cap-
acity also have the potential to affect oxidant-induced
zinc release from protein thiols [40]. To determine if
MT gene dose influences the total intracellular redox
buffering capacity, total reduced cellular thiols were
quantified in MT-/- and wildtype control MT+/+ CD4+
naïve and effector T cells by CPM assay [41]. The con-
centration of reduced thiols was higher in CD4+ Tr1 ef-
fector cells compared with naïve lymphocytes (p < .05),
but was not different between MT-/- and MT+/+ Tr1
cells (Fig. 3a), indicating that the expression of MT did
not significantly alter the total intracellular free thiol
concentration. This is not unexpected, given that
reduced glutathione exists in >1000 fold molar excess
compared to MT in CD4+ T cells [25, 42]. Additionally,
MT expression did not contribute to a significant differ-
ence in the total redox buffering capacity, as shown by
the similar level of oxidation of the fluorescent probe
CM-H2DCF in MT
-/- and MT+/+ Tr1 cells after exposure
to H2O2 (Fig. 3b). These results suggest that MT is not a
significant source of total intracellular free thiols under
these cell culture conditions and that CD4+ T cells
maintain their intracellular redox potential in the
absence of MT. However, when MT is present as part of
the intracellular pool of free thiols, cells maintain a
greater zinc release potential in response to ROS. In this
way, MT serves to amplify zinc signals that are trans-
duced by an initiating oxidant signal without affecting
total intracellular redox buffering capacity or the oxidant
signal itself.
Intracellular ROS generation is an important compo-
nent of effector CD4+ T cell signaling following TcR acti-
vation [39, 43, 44] and is a requirement for effector
function and expression of important regulatory mole-
cules including Fas ligand (FasL). Hydroxyl radicals,
superoxides, hydrogen peroxides, and nitric oxides [45],
have all been shown to release Zn2+ from MT either dir-
ectly [20, 21, 46], or indirectly via a mechanism where
reduced glutathione (GSH) is oxidized to glutathione
disulfide (GSSG), which then oxidizes MT [47]. To
determine if ROS production is affected by the presence
of MT, CD4+ Tr1 cells were stimulated with anti-CD3
cross-linked with anti-IgG, which is sufficient to stimu-
late ROS production in CD4+ T cells [43]. CD4+ Tr1
cells produced a robust intracellular ROS signal within
30 min of TcR stimulation (Fig. 4a) and ROS persisted
for at least 2 h indicated by the oxidation of the CM-
H2DCF probe. Oxidation of the probe after activation
was not significantly higher in MT-/- cells compared
with MT+/+ control cells, further supporting the conclu-
sion that MT is part of a larger intracellular redox-
buffering network and is not essential for maintaining
cellular redox buffering capacity.
Despite similar levels of ROS generation following ac-
tivation, the increase in [Zn2+]i after 1 h of stimulation
was greater in MT+/+ Tr1 cells (Fig. 4b) compared with
MT-/- Tr1 cells. Similar to exogenous hydrogen peroxide
exposure (Fig. 2), this increase was not affected by the
addition of 20 μM ZnSO4 during the initial 3 h time
period, indicating the difference in zinc levels was not
due to a zinc influx from the extracellular environment
(data not shown). The increase in [Zn2+]i following re-
activation of Tr1 cells with anti-CD3 continued for at
least 48 h (Fig. 4c) and the peak [Zn2+]i was higher
during restimulation than during primary activation
(Figs. 1d and 4d). After 8 h of restimulation, the increased
[Zn2+]I was no longer greater in MT
+/+ Tr1 cells




Fig. 2 (See legend on next page.)
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compared with MT -/- Tr1 cells. This suggests that while
immediate increases in [Zn2+]i following reactivation are
affected by the release of Zn2+ from the intracellular
stores, [Zn2+]i 12 h after restimulation Zn
2+ is predomin-
antly regulated by ion transporters associated with T cell
activation [12, 33]. Interestingly, CD4+ effector cells differ-
entiated under Th1 conditions achieved an even higher
[Zn2+]i after 48 h restimulation compared with either Tr1
or Th0 cells, although there was no difference associated
with MT genotype (Additional file 2: Figure S2). This
suggests that different CD4+ T helper subsets regulate
[Zn2+]i differently to mediate effector function.
Intracellular labile zinc can influence T cell signaling
by directly affecting both the STAT [9, 48] and MAPK
pathways [2, 4]. The co-stimulatory effect of Zn2+ on
p38 MAPK signaling in CD4+ T cells has recently been
observed following signaling through both the T cell re-
ceptor [7] and the IL-1 receptor [49]. During activation,
relatively small increases in [Zn2+]i can inhibit protein
tyrosine phosphatase activity [3, 10], which results in in-
creased phosphorylation of p38 MAPK [50]. Other
MAPK proteins are also affected by [Zn2+]i following
stimulation through the TcR including ERK1/2, but
we chose to investigate p38 because the inhibitory
(See figure on previous page.)
Fig. 2 Metallothionein expression in Tr1 cells is associated with increased Zn2+ release following exposure to H2O2 or DTDP. Intracellular Zn
2+
release was measured in Tr1 cells from metallothionein knockout mice (MT-/-) (n = 3) or congenic wildtype control mice (MT+/+) (n = 3) exposed
to different concentrations of H2O2 to measure oxidant-induced Zn
2+ release. a The release of intracellular Zn2+ was measured by an increase in
fluozin-3 fluorescence in wildtype Tr1 cells before and after exposure to H2O2 [5–40 μM] or (b) for metallothionein knockout (MT-/-) Tr1 cells compared
with wildtype controls exposed to H2O2 [40 μM] in one representative sample of each treatment is shown. c The increase in intracellular [Zn2+] after
7 min of H2O2 [1.25–40 μM] exposure was compared using linear regression. d The fold-increase in intracellular [Zn2+] after 100 μM DTDP exposure
was compared using linear regression. Error bars indicate standard deviation
Fig. 3 Metallothionein expression does not affect the total redox buffering capacity of Tr1 cells. CD4+ T cells from metallothionein knockout
(MT-/-) (n = 4) or congenic wildtype control mice (MT+/+) (n = 4) were cultured for 0 (naïve) or 6 days in the presence of Il-27 (Tr1 effector). a Cell
lysate was analyzed for the presence of free thiols by CPM assay and total protein concentration by BCA assay. b Tr1 cells were loaded with the
oxidant sensitive probe CM-H2DCFDA. Fluorescence from the oxidized form of the probe was measured before and after H2O2 [50 μM] or PBS
control exposure for 30 min to determine the intracellular redox buffering capacity. Bars indicate standard deviation. (*p < .05, **p < .01)
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phosphatase that regulates p38 phosphorylation is sensi-
tive to the picomolar increases in [Zn2+]i that were ob-
served when MT was present following restimulation of
Tr1 cells. To determine if a co-stimulatory effect of Zn2+
on p38 activation is associated with a ROS-mediated re-
lease of Zn2+ from MT, phosphorylated p38 was measured
in MT+/+ or MT-/- Tr1 cells during re-stimulation through
the TcR in vitro. Phospho-p38 levels peaked at 10 min
post re-stimulation with anti-CD3 antibody, irrespective
of MT gene dose (Fig. 5a). This increase was significantly
higher in MT+/+ Tr1 cells compared with MT-/- Tr1 cells
and was not a result of differences in total p38 levels
between the two strains (Additional file 3: Figure S3).
An association between MT gene dose and increased
p38 activation was also observed when cells were stimu-
lated with the protein kinase C activator PMA. Peak
levels of phospho-p38 were observed after 20 min of
PMA stimulation in both MT+/+ and MT-/- Tr1 CD4+
cells and were again significantly higher in cells that ex-
press MT (Fig. 5b). PMA treatment did not appear to in-
duce a zinc influx from the extracellular environment
because p38 activation was not affected by increasing
the extracellular [Zn2+] during stimulation with PMA
(Fig. 5c). However, PMA does promote ROS generation
[44] and a subsequent increase in [Zn2+]i [51] in CD4
+ T
effector cells. This suggests zinc released from MT by
ROS increases p38 activation and represents a novel
mechanism for regulating p38 activation through expres-
sion of MT.
Differences in p38 activation mediated by MT were
overcome with the addition of ZnSO4 together with the
zinc ionophore pyrithione, indicating MT-/- Tr1 cells
were capable of achieving levels of p38 activation similar
to MT+/+ cells when sufficient intracellular free zinc was
present. Furthermore, differences in MT expression did
not affect the activation of p38 when the available pool
of intracellular labile zinc was removed by adding the
zinc chelator TPEN (Fig. 5c). The observation that p38
activation was not affected by MT gene dose under
conditions of similar intracellular zinc availability, via





Fig. 4 Metallothionein gene dose affects intracellular [Zn2+] in Tr1
cells following stimulation through the T cell receptor. Tr1 cells from
metallothionein knockout (MT-/-, n = 4) or congentic wildtype control
mice (MT+/+, n = 4) were loaded with CM-H2DCFDA and stimulated
with anti-CD3 [10 μg/mL] cross-linked with anti-hamster IgG [10 μg/
mL] for 0–120 min. a The fold change in CM-H2DCF fluorescence or
(b) intracellular [Zn2+] in stimulated Tr1 cells compared with unstimulated
control cells for each strain at 30, 60 and 120 min is shown. c, d MT+/+
(n = 6) and MT-/- (n = 6) Tr1 cells were stimulated with plate-bound
anti-CD3 [5 μg/mL] for 48 h. c The fold increase in intracellular
[Zn2+] was measured at 4, 8, 12, 24 and 48 h. d The intracellular
[Zn2+] of each sample after 48 h is shown. Error bars indicate standard
deviation. (*p < .05)
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suggests that MT expression affects p38 activation
through the regulation of available intracellular labile zinc.
The downstream effects of increased [Zn2+]i can in-
clude altered effector phenotype and cytokine secretion
[9, 13, 48]. There are reports that MT gene dose can in-
fluence IL-10 expression, but these effects have not been
consistently observed [30, 35]. To determine if MT gene
dose affects the expression of cytokines, we measured
secretion of IL-10 and IFN-gamma from MT+/+ and
MT-/- Tr1 cells. Secretion of IL-10 was detected in the
media by 6 h post stimulation and was greater in MT-/-
Tr1 cell cultures compared with MT+/+ controls at 24
and 48 h post stimulation (Fig. 6a). Secretion of IFN-
gamma during the same time period was not signifi-
cantly affected by MT gene dose (Fig. 6b), suggesting
that the influence of MT on IL-10 secretion is cytokine
specific and not due to a more general effect on the
secretion of all cytokines.
To determine if the elevated IL-10 secretion levels
observed in MT-/- cells were sensitive to [Zn2+]i, the
resting zinc level was increased in Tr1 CD4+ cells by
pre-incubating cells in media containing ZnSO4 [20 μM]
for 24 h before restimulation (Additional file 4: Figure S4).
This enabled us to test the effect of an increased [Zn2+]i in
Tr1 cells during the early activation window (0-6 h) where
MT associated increases in the labile zinc pool had been
observed (Fig. 4b and c). This concentration of ZnSO4 did
not affect cell viability and in the presence of 10 % FBS
(which buffers labile Zn2+ ions), is estimated to increase
the extracellular labile [Zn2+] in media to 10 μM [34].
Increasing the [Zn2+]i during restimulation significantly
decreased IL-10 secretion from MT-/- but not MT+/+ Tr1
cells (Fig. 6c). During the same time period, increasing
[Zn2+]i did not significantly affect IFN-gamma secretion,
further supporting the conclusion that regulation of
effector function by Zn2+ released from MT is cytokine
specific. This is in line with previous studies which found
that pre-incubation in 25 μM zinc aspartate reduced IL-2,
IL-10, and IL-17 secretion following anti-CD3 stimulation
in naïve splenocytes [13]. Our observations support this
finding and suggest that MT mediated differences in IL-10
secretion are mediated through the regulation of [Zn2+]I
in CD4+ Tr1 cells.
Discussion
The relationship between MT expression and immune
function is complex. Both extracellular and intracellular
pools of MT play important roles in modulating immune
responses and influence a range of cellular behaviors in-
cluding chemotaxis [52, 53], apoptosis [54], proliferation
[55], differentiation [30, 56], and resistance to cellular
stress [57] and infection [58]. Furthermore, MT expres-
sion is increased in many pathological conditions [59]




Fig. 5 Metallothionein gene dose affects p38 MAPK activation in a
Zn2+-dependent manner. Tr1 cells from metallothionein knockout
(MT-/-) (n= 4) or wildtype control mice (MT+/+) (n= 4) were stimulated
with (a) plate-bound anti-CD3 [5 μg/mL] or (b) 100 ng/mL PMA for 0–60
min. Cells were fixed, permeabilized and probed for the presence of
phospho-p38. c During PMA induced activation, cells were treated with
ZnSO4 [20 μM] with or without the zinc ionophore pyrithione, or with
the zinc chelator (TPEN). Cells were fixed and permeabilized after 20 min
and probed for and presence of phospho-p38. Error bars indicate
standard deviation. (*p < .05)
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auto-immune diseases [61] and significantly effects the
development of both humoral [62] and cellular adaptive
immune responses [35].
In this study, we have specifically investigated CD4+
Tr1 cell responses in vitro to assess the effect of intracel-
lular MT expression on zinc signaling. The results of
this study demonstrate that intracellular MT plays an
important role as a signal transducer by converting ROS
signals into a transient increase in labile [Zn2+]i follow-
ing Tr1 cell re-activation. The amplitude of this zinc
signal is sufficient to regulate zinc-sensitive signaling
pathways and influence effector function. The ability of
MT to release free zinc ions in response to different
types of cellular stress is well established. However, this
is the first time, to our knowledge, that MT expression
has been shown to strengthen the zinc signal resulting
from T cell activation and have an effect on p38 MAPK
signaling.
The relationship between p38 MAPK signaling and ex-
pression of IL-10 is poorly understood. While it has
been reported that pharmacological inhibition of p38 ac-
tivation down-regulates IL-10 expression [63, 64], much
less is known about the effect of changes in p38 activa-
tion that are confined to the 30 min following stimula-
tion, which were observed in CD4+ T cells that differed
in MT expression. Our results indicate that reduced p38
activation in cells that do not express MT does not
reduce IL-10 or IFN-gamma expression. It is therefore
likely that other zinc sensitive signaling pathways includ-
ing ERK1/2 [7], which have been shown to regulate
IL-10 expression [65], may play a role during Tr1 cell
restimulation and secretion of IL-10.
The control of intracellular labile zinc is a complex
process where the active transport, sequestration, and
release of zinc ions from intracellular thiols in response
to different environmental stimuli are continuously
regulated. The maintenance of zinc homeostasis and the
development of normal T cell responses in CD4+ T cells
from MT knockout mice suggest that MT is only part of
a larger network of zinc regulation. However, recent
evidence has revealed that even small changes in [Zn2+]i
can significantly affect signaling networks, especially those





Fig. 6 Release of the MT-dependent Zn2+ pool decreases IL-10
secretion but does not affect IFN-gamma release. Tr1 induced
splenocyte populations from metallothionein knockout (MT-/-) (n = 3)
or wildtype control mice (MT+/+) (n= 3) were restimulated with anti-CD3
[5 μg/mL] for 48 h. Supernatants were collected at different timepoints
and analyzed for the presence of (a) IL-10 and (b) IFN-gamma by ELISA.
c Tr1 cells from metallothionein knockout (MT-/-) (n= 3) or wildtype
control mice (MT+/+) (n = 3) were pre-incubated with ZnSO4
[20 μM] (to increase intracellular [Zn2+]) or in media alone for 24 h
before being restimulated with anti-CD3 [5 μg/mL] for an additional
24 h. Error bars indicate standard deviation. (*p < .05)
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suggests that the contribution of MT in amplifying
oxidant-induced zinc signals has downstream conse-
quences, even in the presence of other regulators of zinc
homeostasis.
The appropriate upregulation of MT expression in the
presence of cytokines such as IL-27 and IL-6 provides a
mechanism by which MT primes CD4+ T helper cells to
differentially respond to ROS signals following re-
activation and/or exposure to oxidative stress by transi-
ently increasing the [Zn2+]i. The timing and magnitude
of this amplified zinc signal are ideally positioned to
regulate signaling cascades that immediately follow acti-
vation through the T cell receptor. In this way, oxidant-
induced zinc release from MT, in combination with
other pathways of zinc mobilization across plasma and
vesicular membranes, create dynamic intracellular zinc
signals that shape appropriate immune responses. In
contrast to transient MT expression, chronic inflamma-
tion leads to sustained MT overexpression which is asso-
ciated with low intracellular zinc ion bioavailability and
impaired T cell pathway activation in older populations
[66, 67]. These observations underscore a balance where
appropriate increases in MT lead to increased zinc
signaling, proliferation, and immune function while
aberrant overexpression during chronic inflammation
leads to decreased zinc signaling and immune depression.
Conclusions
Previous studies have observed that human CD4+ T cells
express higher levels of MT than other peripheral blood
cell populations and that individual levels of MT induc-
tion in lymphocytes varies considerably within the hu-
man population [68, 69]. Differential transduction and
amplification of zinc signals in CD4+ T cells may help to
explain the association of MT expression with auto-
immune disease, infection and cancer via regulation of
CD4+ T cell signaling. This is especially true when the
consequences of increased MT expression in inflamma-
tory autoimmune disease are divergent. For example,
MT is associated with increased inflammation and
pathogenesis in inflammatory bowel disease models [70]
but suppression of inflammation in models of auto-
immune arthritis [35, 71]. The unique contribution of
MT to ROS-mediated zinc signal transduction provides
further insight into the complex relationship between
MT and inflammation and could represent a novel




All studies were performed using cells from mice bred
and housed at the University of Connecticut in accord-
ance with the University of Connecticut Institutional
Animal Care and Use Committee (IACUC) guidelines.
C57BL/6 J mice (abbreviated MT+/+) were backcrossed
to a Mt1Mt2 knockout strain (129S7/SvEvBrd-Mt1tm1Bri
Mt2tm1Bri ) [72] to yield congenic MT knockout mice
(C57BL/6-Mt1tm1Bri Mt2tm1Bri , abbreviated MT-/- ).
Mice used in these experiments were between 9 and
24 weeks of age and genotypes were verified by PCR ac-
cording to protocols provided by Jackson Laboratory
(www.jax.org). All mice were age- and sex- matched
within each set of experiments.
Reagents
All reagents were molecular biology grade, reconstituted
and stored according to manufacturer’s protocols, and
0.22 μM filter-sterilized before use in cell culture includ-
ing TPEN (N,N,N′,N′-Tetrakis(2-pyridylmethyl) ethylene-
diamine), pyrithione (2-Mercaptopyridine N-oxide sodium
salt), ZnSO4 (zinc sulfate), H2O2 (hydrogen peroxide,
30 % w/v), DTDP (2,2'-dithiodipyridine), PMA (phorbol
12-myristate 13-acetate) (Sigma, St. Louis MO), Fluozin-
3 AM, CM-H2DCFDA (5(and 6)chloromethyl-2',7'-
dichlorodihydrofluorescein diacetate, acetyl ester), and
CPM (7-Diethylamino-3-(4'-Maleimidylphenyl)-4-Methyl-
coumarin) (Life Technologies, Carlsbad, CA).
Labeled antibodies used in flow cytometry included
anti-CD4-alexafluor 647 (clone RM4-5), anti-CD4-FITC
(clone GK1.5), anti-CD4-PE (clone GK 1.5), anti-CD4-
PerCP (clone RM4-5), anti-CD8-PE (clone 53-6.7), anti-
CD25a-PE Cy7 (clone PC61), anti-rabbit IgG FITC (BD
Biosciences, Franklin Lakes, NJ), and Isotype control
IgG-alexafluor647 (mouse IgG1k, clone MOPC21) (Bio-
legend, San Diego, CA). Anti-MT (mouse IgG1k,
clone UC1MT) was produced in-house and labeled
with alexafluor647 using an NHS-alexafluor647 labeling
kit (Life Technologies, Carlsbad, CA). Unlabeled anti-
bodies included anti-phospho p38, anti-p38 (Cell Signal-
ing, Beverly, MA) and isotype control rabbit IgG
(Chemicon, Billerica, MA). Secondary antibody anti-rabbit
IgG-HRP was used for western blotting (BD biosciences,
Franklin Lakes, NJ). Antibodies used for activation of
CD4+ T cells included anti-mouse CD3 (clone 17A2)
(Biolegend, San Diego, CA) and anti-mouse CD28
(clone 37.51) (BD biosciences, Franklin Lakes, NJ) for
plate-bound stimulation, and hamster anti-CD3 (clone
145-2C11) (BD Biosciences, Franklin Lakes, NJ) and
anti-hamster IgG (KPL, Gaithersburg, MD) for stimu-
lation in suspension.
Cell isolation
Spleens were removed aseptically and single cell suspen-
sions were made using frosted glass slides (Corning,
Corning, NY) and passage through an 18-gauge needle
and a 70 μM cell strainer (Fisher, Morris Plains, NJ).
Viable lymphocytes were then enriched by density
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centrifugation using Histopaque 1083 (Sigma, St. Louis,
MO). For CD4+ T cell isolation, cells were isolated using
a negative selection magnetic isolation column (Miltenyi
Biotec, Cambridge, MA) according to manufacturer
instructions.
Media
During splenocyte isolation or during treatment outside of
a CO2 incubator, mouse cells were maintained in DMEM
containing 4.5 g/L glucose, 1 mM sodium pyruvate and
2 mM L glutamine (Gibco, Waltham, MA), supplemented
with 10 % FBS (Hyclone, South Logan, UT), 25 mM
HEPES buffer, 1 % penicillin/streptomycin (Gibco,
Waltham, MA), and 50 μM 2-mercaptoethanol (Fisher,
Morris Plains, NJ). For cell culture, including activation
and differentiation, cells were cultured in the same media
with added 1 % non-essential amino acids (Gibco,
Waltham, MA), and without HEPES using 96 or 24 well
tissue culture treated plates (Fisher, Morris Plains, NJ) at
106 cells/mL for CD4+ T cell culture and 2 x 106 cells/mL
for splenocyte culture at 37 °C and 5 % CO2. For analysis
by flow cytometry, cells were resuspended in Fluorobrite™
DMEM (Gibco, Waltham, MA) with 10 % FBS (Hyclone,
South Logan, UT) and 25 mM HEPES.
Cell activation and differentiation
Mouse splenocytes were incubated in 24 well plates
coated with 1 μg/mL anti-CD3 and 1 μg/mL soluble
anti-CD28. Tr1 inducing conditions: 50 ng/mL of IL-27
(R&D systems, Minneapolis, MN) was added according
to previously described protocols [30]. Th1 inducing
conditions: 20 ng/mL IL-2, 20 ng/mL IL-12, and 10 μg/
mL anti-IL-4 (R&D systems, Minneapolis, MN) was
added. Th0 inducing conditions: no added cytokine.
After 5 days, cells were counted and resuspended at
1x106 cells/mL in 75 % fresh cell culture media (without
cytokines) to rest for 2 days.
Restimulation of mouse CD4+ T cells: Rested cells
were plated at 1 x 106 cells/mL in fresh media in 96 or
24 well plates coated with 5 μg/mL anti-CD3 with a
brief spin (200 x g for 2 min) to ensure contact between
cells and plate bottom. Alternatively, 100 ng/ml PMA
was added to wells. At indicated time points, cells were
collected, put on ice for 3 min and centrifuged at 300 x
g for 5 min at 4 C. Supernatants were stored at -80 C
until cytokine analysis by ELISA. For production of
ROS, cells were coated with anti-CD3 [10 μg/mL] (BD
Biosciences, Franklin Lakes, NJ) on ice and restimulated
by addition of anti-hamster IgG [10 μg/mL] in warm
media according to previously described protocols [43].
Measurement of [Zn2+]i or ROS
Cells were loaded with Fluozin-3 AM [0.5 μM] in
complete media at 37 °C for 30 min. Cells were washed
with media and incubated for an additional 20 min at
37 C. Cells were then stained for surface markers at 4 C
for 20 min. Cells were washed again and resuspended in
Fluorobrite™ media + propidium iodide [2.5 μM] (Life
Technologies, Carlsbad, CA) and subdivided into 3 tubes
(Fmin, F, Fmax) and stored on ice. 10 min before analysis,
an equal volume of TPEN in PBS [100 μM] was added to
each Fmin tube, PBS was added to the F tube, and pyr-
ithione [200 μM]+ ZnSO4 [100 μM] in PBS was added to
the Fmax tube.
To measure changes in [Zn2+]i or ROS production
during stimulation for 0–2 h, cells were loaded with
Fluozin-3 AM [0.5 μM] or CM-H2DCFDA [1 μM],
respectively, and stained with anti-CD4 for the final
10 min of activation. Cells were immediately put on ice,
washed 1x with media, and analyzed by flow cytometry.
Measurement of intracellular thiols
Total intracellular thiols were measured using a N-[4-
(7-diethylamino-4-methyl-3-coumarinyl)phenyl]maleimide
(CPM) assay (Life Technologies, Carlsbad, CA) as described
previously [41]. Briefly, cells were lysed in cell lysis buffer
(0.5 % NP-40 + 1 mM EDTA in PBS) and lysate protein
concentrations were normalized by BCA assay (Thermo-
Fisher, Waltham, MA). Cell lysates (in triplicate) were im-
mediately incubated with CPM and fluorescence was read
on a SpectraMax M2 Plate Reader (ex.387 / em. 465) using
softmax Pro software (Molecular Devices, Sunnyvale, CA)
and compared with a reduced glutathione standard curve
(10 μM–10nM) to quantify intracellular thiols.
Measurement of p38 MAPK
Tr1 cells were activated by briefly centrifuging cells in
media onto 96-well anti-CD3 coated plates [5 μg/ml] or
by adding PMA [100 ng/ml] with or without ZnSO4
[20 μM], pyrithione [50 μM], or TPEN [50 μM]. Cells
were incubated at 37 C for indicated times and then im-
mediately fixed by adding an equal volume of 4 % para-
formaldehyde and incubating for 10 min at 37 C. Cells
were washed 2x with PBS and stained for CD4. Cells
were then permeabilized and stained for phospho-p38
before analyzing by flow cytometry. For western blotting
experiments, cells were activated with anti-CD3 [10 μg/ml]
and anti-hamster IgG [10 μg/ml] for the indicated time
and immediately placed on ice, centrifuged, and lysed
in protease/phosphatase inhibitor cocktail (Roche,
Indianapolis, IN). Lysate protein concentrations were
normalized by BCA assay and separated by SDS-PAGE
before being analyzed by western blot for the presence
of phospho-p38, total-p38, or tubulin.
Measurement of secreted cytokines
IL-10 and IFN-gamma were measured using anti-mouse
IL-10 and anti-mouse IFN-gamma Duoset antibody kits
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(R&D Systems, Minneapolis, MN) and Immulon H2B 96
well plates (Fisher, Morris Plains, NJ). Plates were read
on a SpectraMax Plate Reader using softmax Pro soft-
ware (Molecular Devices, Sunnyvale, CA).
Data analysis
Data was analyzed using Graphpad Prism (v6). Compari-
sons between 2 groups were made using independent
two-tailed T tests and a Sidak-Bonferroni correction
for multiple comparisons where appropriate or 1-way
ANOVA for comparisons of 3 groups. Where Linear
Regression analysis was used, the slopes of best-fit
lines were compared to determine p values.
Additional files
Additional file 1: Figure S1. Increasing extracellular [Zn2+] does not
affect intracellular Zn2+ release following exposure to ROS. Tr1 cells from
metallothionein wildtype control mice were exposed to 5μM H2O2 in
media (circle) or media with 20μM ZnSO4 added (square). Baseline
Fluozin-3 fluorescence was established for 30 s followed by a 7 min
exposure to H2O2. (PDF 109 kb)
Additional file 2: Figure S2. T helper cell inducing conditions have an
effect on the intracellular [Zn2+] of CD4+ T cells during primary activation
and differentiation. Splenocytes from MT knockout (MT-/-) (n = 3–4) or
wildtype controls (MT+/+) (n = 3–4) were stimulated with anti-CD3 and
anti-CD28 for 6 days in the presence of no added cytokines (Th0), IL-12 +
IL-2 + anti-IL-4 (Th1), or IL-27 (Tr1) to promote differentiation and expansion
of T helper cell populations. Intracellular [Zn2+] in the CD4+ T cell population
was measured for each inducing condition and MT genotype at +6 days
post stimulation. (PDF 90 kb)
Additional file 3: Figure S3. MT gene dose does not affect total p38
MAPK levels in CD4+ Tr1 cells. CD4+ Tr1 cells from MT knockout (MT-/-) or
wildtype control (MT+/+) mice were stimulated with anti-CD3 cross-linked
with anti-IgG for 15–120 min or with no cross-linking (timepoint 0). Cell
lysates were analyzed for the presence of total p38 or tubulin by SDS-PAGE
and western blotting. (PDF 68 kb)
Additional file 4: Figure S4. Addition of ZnSO4 [20μM] to cell culture
media for 24 h increases intracellular [Zn2+] in CD4+ Tr1 cells. Tr1 cells
from MT knockout (MT-/-) (n = 6) or wildtype control (MT+/+) mice (n = 6)
were incubated in media + ZnSO4 [20μM] or media alone for 24 h. Tr1
cells were loaded with fluozin-3 AM and the intracellular [Zn2+] was
measured by flow cytometry. (PDF 98 kb)
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